2.00
0.50%
-0.010
전일 마감가:
$2.01
열려 있는:
$1.95
하루 거래량:
3,906
Relative Volume:
0.09
시가총액:
$2.79M
수익:
-
순이익/손실:
$-10.38M
주가수익비율:
-0.3996
EPS:
-5.0046
순현금흐름:
$-12.45M
1주 성능:
+6.38%
1개월 성능:
+0.00%
6개월 성능:
-47.37%
1년 성능:
-86.42%
Avenue Therapeutics Inc Stock (ATXI) Company Profile
명칭
Avenue Therapeutics Inc
전화
781-652-4500
주소
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
ATXI을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
ATXI | 1.98 | 2.79M | 0 | -10.38M | -12.45M | -5.0046 |
VRTX | 449.35 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 749.22 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 587.51 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.60 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.00 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Avenue Therapeutics Inc 주식(ATXI)의 최신 뉴스
Avenue Therapeutics stock hits 52-week low at $1.68 - Investing.com
Avenue Therapeutics Inc (ATXI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Ther - GuruFocus.com
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Canadian North Resources Inc. Announces Appointment Of Henderson Tse To The Board Of Directors - The Manila Times
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Expedia faces threat from tepid growth in 2025, Deutsche Bank says after downgrade - Investing.com
Avenue Therapeutics director Jay Kranzler sells $136 in stock - Investing.com India
Avenue Therapeutics director Jay Kranzler sells $136 in stock By Investing.com - Investing.com UK
APLT (Applied Therapeutics) Cash From Other Investing Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Drug Resistant Epilepsy Market Size, Industry Analysis, - openPR
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
NYC officials envision turning Fifth Avenue into a grand boulevard | Company Business News - Mint
Avenue Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Avenue Therapeutics stock hits 52-week low at $1.89 - Investing.com
Park Avenue Securities LLC Reduces Position in Morningstar, Inc. (NASDAQ:MORN) - Defense World
DMart Q2 Results: Avenue Supermarts net profit rises 5.77% to ₹659.58 crore, revenue up 14.41% YoY | Company Business News - Mint
IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Park Avenue Securities LLC - Defense World
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - StockTitan
Avenue Therapeutics stock hits 52-week low at $2.17 By Investing.com - Investing.com South Africa
Avenue Therapeutics stock hits 52-week low at $2.17 - Investing.com
Avenue Therapeutics director buys shares worth $1,249 By Investing.com - Investing.com South Africa
Avenue Therapeutics director buys shares worth $1,249 - Investing.com India
Frazier Life Sciences Management L.P. Increases Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Avenue Therapeutics grants stock units to top executives By Investing.com - Investing.com Canada
Avenue Therapeutics grants stock units to top executives - Investing.com India
Avenue Therapeutics Incentive Plan Awards Key Executives - TipRanks
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Avenue Therapeutics stock hits 52-week low at $2.23 By Investing.com - Investing.com Canada
Avenue Therapeutics stock hits 52-week low at $2.23 - Investing.com
Avenue Supermart shares rise 1.49% as Sensex climbs - The Economic Times
Avenue Supermart rises 1.49% as Sensex climbs - The Economic Times
Share price of Avenue Supermart falls as Sensex gains 251.05 points - The Economic Times
Victory Capital Management Inc. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Forest Avenue Capital Management LP Has $44.92 Million Position in Walmart Inc. (NYSE:WMT) - Defense World
Postoperative acute pain Market Size is Set for Rapid Growth as - openPR
Forest Avenue Capital Management LP Has $24.54 Million Holdings in GE Vernova Inc. (NYSE:GEV) - Defense World
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
First Avenue IPO on Nomu 740% oversubscribed; offer price set at SAR 6 - بوابة أرقام المالية
Avenue Supermart shares down 0.27% as Nifty gains - The Economic Times
Avenue Supermart shares fall 0.27 per cent in Thursday's trading session - The Economic Times
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - AccessWire
Avenue Supermart shares up 0.35% as Nifty gains - The Economic Times
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
2 Dead In Series Of Police Shootouts That Shut Down Victory Boulevard - Patch
Meet Microsoft’s new COO—a former superstar CFO from GE - Fortune
Share price of Avenue Supermart rises as Nifty strengthens - The Economic Times
Allarity Therapeutics appoints new CFO - Investing.com India
Avenue Therapeutics Inc (ATXI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Avenue Therapeutics Inc 주식 (ATXI) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
KRANZLER JAY D | Director |
Sep 30 '24 |
Buy |
2.50 |
497 |
1,242 |
620 |
KRANZLER JAY D | Director |
Sep 27 '24 |
Buy |
2.40 |
3 |
7 |
123 |
Davidow Robert L | 10% Owner |
Dec 11 '23 |
Sale |
0.14 |
353,000 |
49,600 |
22,000 |
Davidow Robert L | 10% Owner |
Dec 11 '23 |
Sale |
0.14 |
264,000 |
36,960 |
681,000 |
자본화:
|
볼륨(24시간):